How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Buy
68
NBIX Quote, Financials, Valuation and Earnings
Last price:
$139.06
Seasonality move
:
9.43%
Day range:
$135.94 - $139.10
52-week range:
$110.95 - $157.98
Dividend yield:
0%
P/E ratio:
37.27x
P/S ratio:
6.42x
P/B ratio:
5.18x
Volume:
920.8K
Avg. volume:
1M
1-year change:
5.98%
Market cap:
$14.1B
Revenue:
$1.9B
EPS (TTM):
$3.73
Analysts' Opinion
-
Consensus RatingNeurocrine Biosciences has received a consensus rating of Buy. The company's average rating is a Buy based on 15 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $165.72, Neurocrine Biosciences has an estimated upside of 19.2% from its current price of $139.03.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $121.00 representing 12.97% downside risk from its current price of $139.03.
Fair Value
-
According to the consensus of 19 analysts, Neurocrine Biosciences has 19.2% upside to fair value with a price target of $165.72 per share.
NBIX vs. S&P 500
-
Over the past 5 trading days, Neurocrine Biosciences has overperformed the S&P 500 by 0.83% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Neurocrine Biosciences does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Neurocrine Biosciences has grown year-over-year revenues for 13 quarters straight. In the most recent quarter Neurocrine Biosciences reported revenues of $622.1M.
Earnings Growth
-
Neurocrine Biosciences has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Neurocrine Biosciences reported earnings per share of $1.24.
Enterprise value:
12.8B
EV / Invested capital:
4.73x
Price / LTM sales:
6.42x
EV / EBIT:
23.38x
EV / Revenue:
5.73x
PEG ratio (5yr expected):
0.37x
EV / Free cash flow:
29.19x
Price / Operating cash flow:
32.70x
Enterprise value / EBITDA:
22.33x
Gross Profit (TTM):
$2.2B
Return On Assets:
11.76%
Net Income Margin (TTM):
17.21%
Return On Equity:
16.29%
Return On Invested Capital:
15.5%
Operating Margin:
29.71%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $1.4B | $1.8B | $2.2B | $498.8M | $622.1M | |
| Gross Profit | $1.4B | $1.7B | $2.2B | $487.6M | $614.1M | |
| Operating Income | $209.6M | $347.9M | $588.3M | $141.2M | $184.8M | |
| EBITDA | $109M | $299.6M | $575.3M | $146.7M | $191.3M | |
| Diluted EPS | $0.57 | $1.86 | $3.73 | $0.82 | $1.24 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.2B | $1B | $1.2B | $1.6B | $1.9B | |
| Total Assets | $1.5B | $2B | $2.1B | $2.8B | $3.5B | |
| Current Liabilities | $611M | $225.9M | $485.1M | $691.6M | $429.7M | |
| Total Liabilities | $698.3M | $671.3M | $598.8M | $846.1M | $816.1M | |
| Total Equity | $804.3M | $1.3B | $1.5B | $2B | $2.7B | |
| Total Debt | $425M | $330.7M | $169.2M | $169.9M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $200.6M | $409.4M | $476.4M | $212M | $158M | |
| Cash From Investing | -$37.8M | -$380.9M | -$260.3M | -$97.3M | $24.7M | |
| Cash From Financing | -$257.1M | $54.5M | -$161.3M | $18.8M | $26.4M | |
| Free Cash Flow | $177M | $384.7M | $440.1M | $204.4M | $149.9M | |
NBIX
Sector
Market Cap
$14.1B
$46.1M
Price % of 52-Week High
88.01%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
5.98%
-30.52%
Beta (5-Year)
0.340
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$136.02
200-day SMA
Buy
Level
$133.09
Bollinger Bands (100)
Buy
Level
115.21 - 138.45
Chaikin Money Flow
Buy
Level
37.2M
20-day SMA
Buy
Level
$130.74
Relative Strength Index (RSI14)
Buy
Level
71.82
ADX Line
Buy
Level
11.21
Williams %R
Sell
Level
-6.7408
50-day SMA
Buy
Level
$125.01
MACD (12, 26)
Buy
Level
3.62
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
62.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.8602)
Buy
CA Score
(Annual)
Level (1.2615)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-2.3628)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Stock Forecast FAQ
In the current month, NBIX has received 15 Buy ratings 4 Hold ratings, and 0 Sell ratings. The NBIX average analyst price target in the past 3 months is $165.72.
-
Where Will Neurocrine Biosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Neurocrine Biosciences share price will rise to $165.72 per share over the next 12 months.
-
What Do Analysts Say About Neurocrine Biosciences?
Analysts are divided on their view about Neurocrine Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Neurocrine Biosciences is a Sell and believe this share price will drop from its current level to $121.00.
-
What Is Neurocrine Biosciences's Price Target?
The price target for Neurocrine Biosciences over the next 1-year time period is forecast to be $165.72 according to 19 Wall Street analysts, 15 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is NBIX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Neurocrine Biosciences is a Buy. 15 of 19 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NBIX?
You can purchase shares of Neurocrine Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Neurocrine Biosciences shares.
-
What Is The Neurocrine Biosciences Share Price Today?
Neurocrine Biosciences was last trading at $139.06 per share. This represents the most recent stock quote for Neurocrine Biosciences. Yesterday, Neurocrine Biosciences closed at $139.03 per share.
-
How To Buy Neurocrine Biosciences Stock Online?
In order to purchase Neurocrine Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 43x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
57
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
64
ARQQ alert for Dec 27
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
64
QMCO alert for Dec 27
Quantum [QMCO] is up 49.62% over the past day.
Buy
65
ALGS alert for Dec 27
Aligos Therapeutics [ALGS] is up 10.88% over the past day.
